Back to news

Why Moderna (MRNA) Stock Is Up Today

Investivoq PriceTracker

Moderna (MRNA) is up 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is renewed investor positioning ahead of a high-profile presentation of full Phase 3 melanoma data for Moderna’s personalized cancer vaccine program with Merck at the ESMO Congress on October 24, 2026. The move also appears to have been helped by an analyst price-target increase issued today, which added support even though the rating was unchanged.

Details:

  • Moderna and Merck announced in August that their Phase 3 INTerpath-001 study met its main goal of improving recurrence-free survival and a key secondary goal of improving distant metastasis-free survival in patients with resected melanoma.
  • That result was notable because it marked the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy, giving the oncology pipeline far more weight in Moderna’s valuation.
  • Investors are now looking ahead to the full dataset, which is scheduled for presentation at the ESMO Congress on Saturday, October 24, 2026, creating a near-term catalyst for the shares.
  • Sentiment was likely reinforced by a same-day price-target increase to $220 from $200 by a large brokerage firm, suggesting improving confidence in the company’s cancer-platform potential.

    • Sources:

    Merck, Moderna, Google Finance, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $MRNA Insider Trading Activity

    MRNA Insider Trades

    $MRNA insiders have traded $MRNA stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.

    Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

    • STEPHEN HOGE (President) has made 0 purchases and 8 sales selling 318,952 shares for an estimated $37,631,803.
    • STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
    • JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
    • SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
    • NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
    • ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive MRNA Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $MRNA Hedge Fund Activity

    We have seen 389 institutional investors add shares of $MRNA stock to their portfolio, and 339 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • FMR LLC added 6,187,867 shares (+13.5%) to their portfolio in Q2 2026, for an estimated $433,336,326
    • D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
    • PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
    • CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
    • ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
    • BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $MRNA Congressional Stock Trading

    Members of Congress have traded $MRNA stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:

    • REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 1 purchase worth up to $15,000 on 08/19 and 2 sales worth up to $30,000 on 09/24, 08/19.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $MRNA Price Targets

    Multiple analysts have issued price targets for $MRNA recently. We have seen 7 analysts offer price targets for $MRNA in the last 6 months, with a median target of $45.0.

    Here are some recent targets:

    • Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
    • Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
    • Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
    • Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
    • Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
    • Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
    • Eliana Merle from UBS set a target price of $45.0 on 05/04/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.